Dr. Robin Hsiung | UBC Neurology

Dr. Robin Hsiung, MD

Claim this profile

UBC Hospital

Studies Alzheimer's Disease
Studies Dementia
10 reported clinical trials
16 drugs studied

Area of expertise

1Alzheimer's Disease
Robin Hsiung, MD has run 8 trials for Alzheimer's Disease. Some of their research focus areas include:
APP positive
PSEN1 positive
PSEN2 positive
2Dementia
Robin Hsiung, MD has run 6 trials for Dementia. Some of their research focus areas include:
APP positive
PSEN1 positive
PSEN2 positive

Affiliated Hospitals

Image of trial facility.
UBC Hospital
Image of trial facility.
University Of British Columbia Hospital

Clinical Trials Robin Hsiung, MD is currently running

Image of trial facility.

Gantenerumab

for Alzheimer's Disease

The purpose is to evaluate the biomarker effect, safety, and tolerability of investigational study drugs in participants who are known to have an Alzheimer's disease (AD)-causing mutation. Stage 1 will determine if treatment with the study drug prevents or slows the rate of amyloid beta (Aβ) pathological disease accumulation demonstrated by Aβ positron emission tomography (PET) imaging. Stage 2 will evaluate the effect of early Aβ plaque reduction/prevention on disease progression by assessing downstream non-Aβ biomarkers of AD (e.g., CSF total tau, p-tau, NfL) compared to an external control group from the DIAN-OBS natural history study and the DIAN-TU-001 placebo-treated participants.
Recruiting0 awards Phase 2 & 310 criteria
Image of trial facility.

Remternetug

for Alzheimer's Disease

The purpose of this research study is to test the study drug, referred to as remternetug, to determine its effectiveness for the study treatment of asymptomatic (at risk) Alzheimer disease in individuals with AD-causing mutations. This study will also investigate the effects of remternetug on biomarkers (measures of the disease including brain scans, blood and spinal fluid tests), examine safety data to identify any potential benefits or risks, and examine how well participants can tolerate remternetug. Stage 1 will determine if treatment with the study drug prevents or reverses amyloid beta (Aβ) accumulation compared with placebo in participants with dominantly inherited Alzheimer's disease (DIAD). Stage 2 will evaluate the effect of early anti-amyloid treatment on downstream biomarkers of AD in treated participants compared to external control groups.
Recruiting0 awards Phase 2 & 32 criteria

More about Robin Hsiung, MD

Clinical Trial Related7 years of experience running clinical trials · Led 10 trials as a Principal Investigator · 4 Active Clinical Trials
Treatments Robin Hsiung, MD has experience with
  • Lecanemab
  • Gantenerumab
  • E2814
  • Solanezumab
  • Matching Placebo (Gantenerumab)
  • Matching Placebo (E2814)

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Robin Hsiung, MD specialize in?
Is Robin Hsiung, MD currently recruiting for clinical trials?
Are there any treatments that Robin Hsiung, MD has studied deeply?
What is the best way to schedule an appointment with Robin Hsiung, MD?
What is the office address of Robin Hsiung, MD?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security